View Exam | PowerPak

1. Multiple states have created medical and adult use marijuana programs. Which of the following is TRUE regarding state marijuana programs?

A. State marijuana programs are designed to mirror federal legislature regarding cannabis B. With limited federal direction, each state has developed marijuana programs that can differ substantially C. States have developed uniform laws and regulations regarding marijuana use in anticipation of federal descheduling of marijuana D. Recent changes in the Farm Bill of 2018 have effectively invalidated state-level medical and adult-use marijuana programs E. Unsure

2. Which of the following naturally occurring phytochemicals in marijuana is known to cause euphoria but to a lesser extent than delta-9-tetrahydrocannabinol (THC)?

A. Delta-8-tetrahydrocannabinol (d8-THC) B. 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) C. Cannabigerol (CBG) D. Cannabidiol (CBD) E. Unsure

3. Which of the following seizure disorders is not an approved indication for Epidiolex (cannabidiol)?

A. Juvenile myoclonic epilepsy B. Lennox-Gastaut syndrome C. Dravet syndrome D. Tuberous sclerosis complex E. Unsure

4. Which of the following laws effectively descheduled hemp, defined as having ?0.3% THC?

A. Marijuana Tax Act of 1937 B. California Proposition 215 C. The Agriculture Improvement Act of 2018 D. The Controlled Substances Act E. Unsure

5. CL is a 7-year-old boy (18 kg) with a history of seizures caused by Lennox-Gastaut syndrome who is currently being treated with topiramate 25 mg daily and clobazam 20 mg daily. To improve seizure management, his physician prescribed Epidiolex (cannabidiol) at a starting dose of 45 mg twice daily. Which of the following dose adjustments should be considered as result of adding cannabidiol to his treatment regimen?

A. Reducing clobazam dose due to induction of CYP2C19 B. Reducing topiramate dose due to induction of CYP3A4 C. Increasing clobazam dose due to inhibition of CYP2C19 D. Increasing topiramate dose due to inhibition of CYP3A4 E. Unsure

6. When the parents of CL pick up the prescription for Epidiolex, they see a myriad of CBD products on the OTC shelves of the pharmacy, many of which are less expensive than the prescription product. The parents ask you, the dispensing pharmacist, why they should use the prescription product rather than an OTC product. Which of the following would be the most appropriate response?

A. The OTC products will not be covered by prescription drug insurance B. Substitution between the OTC and prescription products would be appropriate in this circumstance C. The OTC products have higher concentrations of CBD and would not be appropriate for their child D. The prescription product should be used as it is the only FDA-approved CBD product for Lennox-Gastaut syndrome E. Unsure

7. As an independent pharmacy owner, you look to add CBD products to your OTC retail shelves. Which of the following should be considered when selecting a line of CBD products?

A. Adding food products that contain CBD B. Including products with multiple routes of administration, including ophthalmic products C. Ensuring that CBD products list the medical conditions they treat D. Ensuring the availability of a certificate of analysis E. Unsure

8. Which of the following most accurately describes the molecular pharmacology of THC in the endocannabinoid system?

A. Partial agonist of the CB1 receptor; antagonist of the CB2 receptor B. Partial agonist of both CB1 and CB2 receptors C. Antagonist of the CB1 receptor; partial agonist of the CB2 receptor D. Antagonist of both CB1 and CB2 receptors E. Unsure

9. Which of the following most accurately describes the molecular pharmacology of CBD in the endocannabinoid system?

A. Competitive antagonist of the CB1 receptor; agonist of the CB2 receptor B. Partial agonist of both CB1 and CB2 receptors C. Inverse agonist of the CB1 receptor; noncompetitive antagonist of the CB2 receptor D. Noncompetitive antagonist of the CB1 receptor; inverse agonist of the CB2 receptor E. Unsure

10. As recognized drug experts, pharmacists will increasingly provide consultation on the use of OTC CBD products, prescription CBD and THC products, and medical marijuana. Which of the following is a common challenge for pharmacists in being prepared for such consultations?

A. Abundance of published clinical trial data with CBD and THC B. Consistent pharmacist roles in medical marijuana programs C. Limited education on CBD, THC, and marijuana in pharmacy schools and colleges D. Changes in the Farm Bill of 2018 that allow pharmacists to dispense CBD products E. Unsure

Evaluation Questions

11. How confident are in your treatment choice for your patient CL?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Multiple states have created medical and adult use marijuana programs. Which of the following is TRUE regarding state marijuana programs?

2. Which of the following naturally occurring phytochemicals in marijuana is known to cause euphoria but to a lesser extent than delta-9-tetrahydrocannabinol (THC)?

3. Which of the following seizure disorders is not an approved indication for Epidiolex (cannabidiol)?

4. Which of the following laws effectively descheduled hemp, defined as having ?0.3% THC?

7. As an independent pharmacy owner, you look to add CBD products to your OTC retail shelves. Which of the following should be considered when selecting a line of CBD products?

8. Which of the following most accurately describes the molecular pharmacology of THC in the endocannabinoid system?

9. Which of the following most accurately describes the molecular pharmacology of CBD in the endocannabinoid system?

10. As recognized drug experts, pharmacists will increasingly provide consultation on the use of OTC CBD products, prescription CBD and THC products, and medical marijuana. Which of the following is a common challenge for pharmacists in being prepared for such consultations?

Evaluation Questions

11. How confident are in your treatment choice for your patient CL?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Multiple states have created medical and adult use marijuana programs. Which of the following is TRUE regarding state marijuana programs?

2. Which of the following naturally occurring phytochemicals in marijuana is known to cause euphoria but to a lesser extent than delta-9-tetrahydrocannabinol (THC)?

3. Which of the following seizure disorders is not an approved indication for Epidiolex (cannabidiol)?

4. Which of the following laws effectively descheduled hemp, defined as having ?0.3% THC?

7. As an independent pharmacy owner, you look to add CBD products to your OTC retail shelves. Which of the following should be considered when selecting a line of CBD products?

8. Which of the following most accurately describes the molecular pharmacology of THC in the endocannabinoid system?

9. Which of the following most accurately describes the molecular pharmacology of CBD in the endocannabinoid system?

10. As recognized drug experts, pharmacists will increasingly provide consultation on the use of OTC CBD products, prescription CBD and THC products, and medical marijuana. Which of the following is a common challenge for pharmacists in being prepared for such consultations?

Evaluation Questions

11. How confident are in your treatment choice for your patient CL?

« Return to Activity

Customers who Purchased
this Activity also Purchased